Silence Therapeutics Q1 2024 Financials Filed
Ticker: SLNCF · Form: 6-K · Filed: May 16, 2024 · CIK: 1479615
| Field | Detail |
|---|---|
| Company | Silence Therapeutics PLC (SLNCF) |
| Form Type | 6-K |
| Filed Date | May 16, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: financials, quarterly-report
TL;DR
Silence Therapeutics dropped Q1 2024 financials on 5/16. Check the 6-K for details.
AI Summary
Silence Therapeutics plc filed a 6-K on May 16, 2024, reporting its unaudited financial statements for the three months ended March 31, 2024. The filing includes the condensed consolidated interim financial statements, Management's Discussion and Analysis, and Risk Factors sections.
Why It Matters
This filing provides investors with the latest unaudited financial performance and key business updates for Silence Therapeutics for the first quarter of 2024.
Risk Assessment
Risk Level: low — This is a routine financial filing and does not introduce new risks.
Key Players & Entities
- Silence Therapeutics plc (company) — Registrant
- May 16, 2024 (date) — Filing date
- March 31, 2024 (date) — End of reporting period
FAQ
What period do the unaudited financial statements cover?
The unaudited financial statements cover the three months ended March 31, 2024.
What type of company is Silence Therapeutics plc?
Silence Therapeutics plc is a pharmaceutical preparations company.
What is the SEC file number for this filing?
The SEC file number is 001-39487.
When was this Form 6-K filed?
This Form 6-K was filed on May 16, 2024.
What additional sections are included in this 6-K filing besides the financial statements?
The filing also includes Management's Discussion and Analysis and Risk Factors sections.
Filing Stats: 319 words · 1 min read · ~1 pages · Grade level 12.4 · Accepted 2024-05-16 14:21:17
Filing Documents
- sln-6-k-q1_24_final.htm (6-K) — 28KB
- sln-ex99_1.htm (EX-99.1) — 928KB
- 0000950170-24-060977.txt ( ) — 957KB
From the Filing
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of May 2024 Commission File Number: 001-39487 Silence Therapeutics plc (Exact Name of Registrant as Specified in Its Charter) 72 Hammersmith Road London W14 8TH United Kingdom (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F  Form 40-F  Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  On May 16, 2024, Silence Therapeutics plc published its unaudited financial statements for the three months ended March 31, 2024. The unaudited condensed consolidated interim financial statements, as well as the Management’s Discussion and Analysis and Risk Factors sections, are attached hereto as Exhibit 99.1 to this Report on Form 6-K. This Report on Form 6-K (including Exhibit 99.1) shall be deemed to be incorporated by reference into the registration statements on Form S-8 (File Nos. 333-248682 and 333-273576) and Form F-3 (File No. 333-260265) of Silence Therapeutics plc and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished. EXHIBIT INDEX Exhibit No. Description 99.1 Report for the Three Months Ended March 31, 2024 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Silence Therapeutics plc By: /s/ Craig Tooman Name: Craig Tooman Title: President and Chief Executive Officer Date: May 16, 2024